10 research outputs found
Nowcasting inflation with Lasso-regularized vector autoregressions and mixed frequency data
We evaluate the predictive performances of the least absolute shrinkage and selection operator (Lasso) as an alternative shrinkage method for high-dimensional vector auto-regressions. The analysis extends the Lasso-based multiple equations regularization to a mixed/high-frequency data setting. Very short-term forecasting (nowcasting) is used to target the Euro area's inflation rate. We show that this approach can outperform more standard nowcasting tools in the literature, producing nowcasts that closely follow actual data movements. The proposed tool can overcome information and policy decision problems related to the substantial publishing delays of macroeconomic aggregates
Effect of the Scanning Speed of Treatment on the Microstructure, Microhardness, Wear, and Corrosion Behavior of Laser Metal-Deposited Ti–6AL–4V/TiC Composite
An original LIBS system based on TEA CO2 laser as a tool for determination of glass surface hardness
Osteoblast differentiation is enhanced by a nano-to-micro hybrid titanium surface created by Yb:YAG laser irradiation
Deletion of Limk1 and Limk2 in mice does not alter cochlear development or auditory function
Intravenous NPA for the treatment of infarcting myocardium early: InTIME-II, a double-blind comparison on of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction
Aims to compare the efficacy and safety of lanoteplase, a single-bolus thrombolytic drug derived from alteplase tissue plasminogen activator, with the established accelerated alteplase regimen in patients presenting within 6 h of onset of ST elevation acute myocardial infarction. Methods and Results 15 078 patients were recruited from 855 hospitals worldwide and randomized in a 2:1 ratio to receive either lanoteplase 120 KU. kg-1 as a single intravenous bolus, or up to 100 mg accelerated alteplase given over 90 min. The primary end-point was all-cause mortality at 30 days and the hypothesis was that the two treatments would be equivalent. By 30 days, 6.61% of alteplase-treated patients and 6.75% lanoteplase-treated patients had died (relative risk 1.02). Total stroke occurred in 1.53% alteplase- and 1.87% lanoteplase-treated patients (ns); haemorrhagic stroke rates were 0.64% alteplase and 1.12% lanoteplase (P=0.004). The net clinical deficit of 30-day death or non-fatal disabling stroke was 7.0% and 7.2%, respectively. By 6 months, 8.8% of alteplase-treated patients and 8.7% of lanoteplase-treated patients had died. Conclusion Single-bolus weight-adjusted lanoteplase is an effective thrombolytic agent, equivalent to alteplase in terms of its impact on survival and with a comparable risk-benefit profile. The single-bolus regimen should shorten symptoms to treatment times and be especially convenient for emergency department or out-of-hospital administration. (C) 2000 The European Society of Cardiology